Nearly a quarter of advanced lung cancer patients fail to receive epidermal growth factor receptor (EGFR) gene mutation test results before starting treatment, according to a new survey of oncologists in 10 countries.

Cancer Society's Retiring Chief Shares Parting Thoughts

Nearly a quarter of advanced lung cancer patients fail to receive epidermal growth factor receptor (EGFR) gene mutation test results before starting treatment, according to a new survey of oncologists in 10 countries.

Extracellular cysteine/cystine redox regulates the p44/p42 MAPK pathway by metalloproteinase-dependent epidermal growth factor receptor sign...

Extracellular cysteine/cystine redox regulates the p44/p42 MAPK pathway by metalloproteinase-dependent epidermal growth factor receptor sign...

National Guideline Clearinghouse | Chemotherapy and targeted therapy for women with human epidermal growth factor receptor 2–negative (or unknown) advanced breast cancer: American Society of Clinical Oncology clinical practice guideline.

National Guideline Clearinghouse | Chemotherapy and targeted therapy for women with human epidermal growth factor receptor 2–negative (or unknown) advanced breast cancer: American Society of Clinical Oncology clinical practice guideline.

Cancer and the Epidermal Growth Factor Receptor

Cancer and the Epidermal Growth Factor Receptor

Several biomarkers have been identified by high-throughput technologies, but only hormone receptors, such as estrogen (ER), progesterone (PR), and human epidermal growth factor receptor 2 (HER2), are routinely used clinically for breast cancer prognosis and therapeutic purposes

Several biomarkers have been identified by high-throughput technologies, but only hormone receptors, such as estrogen (ER), progesterone (PR), and human epidermal growth factor receptor 2 (HER2), are routinely used clinically for breast cancer prognosis and therapeutic purposes

Niclosamide inhibits epithelial-mesenchymal transition and tumor growth in lapatinib-resistant human epidermal growth factor receptor 2-positive breast cancer — ScienceDirect

Niclosamide inhibits epithelial-mesenchymal transition and tumor growth in lapatinib-resistant human epidermal growth factor receptor 2-positive breast cancer — ScienceDirect

The U.S. Food and Drug Administration approved Gilotrif (afatinib) for patients with late stage (metastatic) non-small cell lung cancer (NSCLC) whose tumors express specific types of epidermal growth factor receptor (EGFR) gene mutations, as detected by an FDA-approved test.

The U.S. Food and Drug Administration approved Gilotrif (afatinib) for patients with late stage (metastatic) non-small cell lung cancer (NSCLC) whose tumors express specific types of epidermal growth factor receptor (EGFR) gene mutations, as detected by an FDA-approved test.

Hyperactive epidermal growth factor receptor (EGFR) signaling and cancer development have been linked.

Hyperactive epidermal growth factor receptor (EGFR) signaling and cancer development have been linked.

Pinterest
Search